Who
Barry D. Quart
Director
Company insider
Files Form 4 as: Director, Kiniksa Pharmaceuticals International; Chief Executive Officer, Heron Therapeutics; Director, Synageva Biopharma; President and CEO, Ardea Biosciences, Inc./DE.
In numbers
- Trades disclosed
- 290
- Buys
- 3
- Sells
- 28
- Bought
- $597K
- Sold
- $17.6M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 21 Dec 2006
- Last trade
- 19 Aug 2026
- Last filed
- 21 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Aug 2026filed 21 Aug 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code G | —2,600 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code G | —2,600 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —2,799 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —12,158 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —2,026 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —12,158 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —2,026 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,799 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,799 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —2,799 | filing |
| 28 Apr 2026filed 29 Apr 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | $188K13,099 at $14.33 | filing |
| 28 Apr 2026filed 29 Apr 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Sold | $656K13,099 at $50.10 | filing |
| 28 Apr 2026filed 29 Apr 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —13,099 at $0.00 | filing |
| 28 Apr 2026filed 29 Apr 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —13,099 at $0.00 | filing |
| 28 Apr 2026filed 29 Apr 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | $188K13,099 at $14.33 | filing |
| 28 Apr 2026filed 29 Apr 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Sold | $656K13,099 at $50.10 | filing |
| 6 Apr 2026filed 8 Apr 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | $99K6,901 at $14.33 | filing |
| 6 Apr 2026filed 8 Apr 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Sold | $345K6,901 at $50.00 | filing |
| 6 Apr 2026filed 8 Apr 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —6,901 at $0.00 | filing |
| 6 Apr 2026filed 8 Apr 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —6,901 at $0.00 | filing |
News
Head to Head Review: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Zenas BioPharma (NASDAQ:ZBIO)KNSA · themarketsdaily.com · 18 Oct 2026
0 headlines in the last 90 days name Barry D. Quart; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.